WallStSmart

IRIDEX Corporation (IRIX)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 49998% more annual revenue ($25.84B vs $51.57M). SYK leads profitability with a 14.4% profit margin vs -6.9%. IRIX appears more attractively valued with a PEG of 0.94. SYK earns a higher WallStSmart Score of 67/100 (B-).

IRIX

Avoid

32

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 7.7Quality: 4.5
Piotroski: 4/9Altman Z: -2.51

SYK

Strong Buy

67

out of 100

Grade: B-

Growth: 8.0Profit: 8.0Value: 4.7Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IRIXUndervalued (+74.4%)

Margin of Safety

+74.4%

Fair Value

$5.59

Current Price

$0.66

$4.93 discount

UndervaluedFair: $5.59Overvalued
SYKSignificantly Overvalued (-19.9%)

Margin of Safety

-19.9%

Fair Value

$229.73

Current Price

$275.56

$45.83 premium

UndervaluedFair: $229.73Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IRIX1 strengths · Avg: 8.0/10
PEG RatioValuation
0.948/10

Growing faster than its price suggests

SYK4 strengths · Avg: 8.3/10
Market CapQuality
$105.70B9/10

Large-cap with strong market position

Operating MarginProfitability
27.0%8/10

Strong operational efficiency at 27.0%

EPS GrowthGrowth
44.1%8/10

Earnings expanding 44.1% YoY

Free Cash FlowQuality
$1.06B8/10

Generating 1.1B in free cash flow

Areas to Watch

IRIX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$12.20M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.103/10

Elevated debt levels

Return on EquityProfitability
-126.4%2/10

ROE of -126.4% — below average capital efficiency

SYK2 concerns · Avg: 3.5/10
P/E RatioValuation
28.0x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : IRIX

The strongest argument for IRIX centers on PEG Ratio. PEG of 0.94 suggests the stock is reasonably priced for its growth.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap, Operating Margin, EPS Growth. PEG of 1.15 suggests the stock is reasonably priced for its growth.

Bear Case : IRIX

The primary concerns for IRIX are EPS Growth, Market Cap, Debt/Equity.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

IRIX profiles as a turnaround stock while SYK is a value play — different risk/reward profiles.

SYK carries more volatility with a beta of 0.77 — expect wider price swings.

SYK is growing revenue faster at 9.4% — sustainability is the question.

SYK generates stronger free cash flow (1.1B), providing more financial flexibility.

Bottom Line

SYK scores higher overall (67/100 vs 32/100). IRIX offers better value entry with a 74.4% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

IRIDEX Corporation

HEALTHCARE · MEDICAL DEVICES · USA

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic laser systems, delivery devices, and consumable instrumentation to treat vision-threatening eye diseases in ophthalmology. The company is headquartered in Mountain View, California.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?